Articles tagged with Acquired Immune Deficiency Syndrome
A new study by Stanford University School of Medicine researchers found that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) contributed to a significant decline in adult death rates from all causes in Africa. The program saved over 740,000 lives between 2004 and 2008 in nine countries targeted by PEPFAR.
A study found that African countries with more intense PEPFAR assistance experienced lower all-cause adult mortality rates, with an estimated 740,914 deaths averted. The initiative also showed significant reductions in HIV-specific deaths.
A study on Rwanda found that HIV/AIDS funding has no adverse effects on non-AIDS health services, and may even improve overall quality of care. The research suggests that comprehensive HIV/AIDS interventions can provide better preventive care, including superior delivery of childhood vaccinations.
Researchers at Mount Sinai School of Medicine discovered that marijuana-like chemicals trigger receptors on human immune cells that directly inhibit a type of human immunodeficiency virus (HIV) found in late-stage AIDS. This finding could lead to the development of new drugs to slow the progression of disease.
The International Association of Physicians in AIDS Care published new evidence-based guidelines to overcome barriers to optimal HIV care. The guidelines address key areas such as entry into care, monitoring adherence, and education, with a focus on special populations like children and adolescents.
The new guidelines, drawn from 325 studies with tens of thousands of people infected with HIV, aim to improve entry into treatment plans and adherence to lifelong drug therapy. Key strategies include systematic monitoring, patient navigators, and automated tracking systems to follow up with patients.
A new research collection highlights the prevalence of improper condom use worldwide, citing common challenges in the US and globally. The study emphasizes the need for improved education and access to condoms to reduce unplanned pregnancies and STIs.
The authors argue that HAART roll-out's cost-effectiveness has been significantly understated, as economic analyses fail to account for its role in preventing HIV transmission. This oversight highlights the need for expanded 'Seek, Test, Treat and Retain' programs to control HIV and AIDS-related morbidity, mortality, and transmission.
The HPTN 052 study found that early treatment with antiretroviral therapy can reduce HIV transmission in couples by at least 96%. The research has been recognized as a scientific breakthrough of the year, inspiring efforts to end the world's AIDS epidemic.
The scale-up of voluntary medical male circumcision is a cost-effective way to prevent HIV in eastern and southern Africa. The initiative aims to achieve 80% coverage of VMMC services in 14 priority countries, resulting in net savings of $16.5 billion between 2011 and 2025.
Researchers create cats with intrinsic immunity to feline AIDS by inserting protective protein genes. The technique, called gamete-targeted lentiviral transgenesis, also makes the offspring glow green for tracking purposes.
A new article in PLOS Medicine suggests that improvements in advocacy, national planning, resource allocation, long-term investments, and health system strengthening are needed to tackle non-communicable diseases. The authors argue that lessons learned from the global AIDS response can inform a successful NCD response.
A recent study from Duke University Medical Center reveals that Cryptococcus gattii is more commonly found in AIDS patients than previously thought. This distinction could lead to differences in treatment and clinical outcomes, as C. gattii may exhibit resistance to commonly used antifungal drugs.
The FDA has cleared a new diagnostic test that detects the cryptoccocal antigen, allowing for early diagnosis and treatment of cryptococcosis. The rapid blood test, known as the CrAg Lateral Flow Assay, is designed for resource-limited settings and can be administered in just a few minutes.
A novel intervention strategy aims to provide HIV testing, medical care, and prevention services to this growing population. The YMSM of Color Initiative focuses on outreach, access to medical care, and preventing HIV transmission.
Researchers stress need for long-term response to AIDS, citing financing, retention, and socio-political instability as major challenges. Social scientists urged to take part in policy-making table.
The International AIDS Society advocates for an expanded global HIV strategy that incorporates 'Treatment as Prevention' to reduce transmission and prevent the onset of AIDS. This approach promotes widespread HIV testing and facilitated access to free treatment for all medically eligible individuals.
The Gladstone Institutes will explore the molecular basis of HIV latency and develop inhibitors against cellular proteins to potentially cure HIV-infected patients. The funding is part of the National Institute of Allergy and Infectious Diseases' Martin Delaney Collaboratory initiative.
The International AIDS Society announced six winners of prestigious scientific awards to be presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. These awards recognize innovative HIV research throughout the world, highlighting the challenges faced by women and girls in the epidemic.
A new mathematical model predicts the location of mutations that lead to HIV-drug resistance, providing a potential solution to improve anti-HIV drug design. The study suggests that understanding these physical properties and interactions can help develop better strategies for combating the virus.
A study by USC researchers reveals that the inefficiency of activation-induced deoxycytidine deaminase is key to generating antibody diversity, a crucial component of the immune system. The enzyme's random process creates mutations in immunoglobulin genes, producing a diverse array of antibodies.
The newest AIDS drug, Edurant, was developed by Rutgers scientists after 13-year collaboration with Janssen Pharmaceutica. The drug has shown exceptional potency against drug-resistant HIV, with 83% of trial participants having undetected HIV levels.
This observational cohort study found HAART markedly improves the survival of HIV-infected children in a severely resource-deprived country. The treatment's effectiveness was comparable to that seen in more affluent settings, addressing a significant need for information on its impact in low-income countries.
A new HIV investment model is proposed to achieve a more targeted and strategic approach to HIV/AIDS funding. The model would require 30% more funding, estimated at $22 billion annually by 2015, to avoid 12.2 million new infections and 7.4 million deaths between 2011 and 2020.
Researchers aim to efficiently identify more HIV-infected people through expanded voluntary testing programs. They also seek innovative approaches to curing HIV/AIDS by eradicating or suppressing the virus in infected individuals.
Drs. Fauci and Dieffenbach emphasize the importance of antiretroviral therapy (ART) in controlling HIV transmission, with early treatment preventing 96% of transmission in a clinical trial. They also highlight the need for a cure and new biomedical prevention therapies to ultimately end the epidemic.
Researchers Peter Cummings and Michael Simpson propose that mimicking natural processes can lead to more efficient and reliable devices. By exploiting contrarian behavior and 'noise,' scientists can develop technology that outperforms traditional methods, as seen in the humble bacterial cell's ability to withstand modern medicines.
Researchers discovered a protein in a single-celled fungus that helps it survive in low-oxygen settings, which may aid humans with compromised immune systems. The discovery identified key genes responsible for the protein's cutting mechanism, offering potential targets for new fungal infection treatments.
Scientists have engineered a protein fragment that prevents the AIDS virus from entering cells, offering a potential breakthrough in treating and preventing HIV/AIDS infection. The discovery is based on a naturally occurring protein called RANTES, which was modified to remove harmful effects while maintaining its therapeutic properties.
A UCLA study reveals HIV causes rapid aging in CD4+ T-cells, leading to accelerated aging and increased risk of age-related diseases. Researchers found that infected individuals exhibit premature telomere shortening, a hallmark of cellular aging.
The report features nearly 500 women from HIV-affected communities who shared their thoughts on medical male circumcision for HIV prevention. Women expressed excitement but also concerns about its benefits and risks, highlighting the need for education campaigns tailored to women's experiences.
The US PLWHA death rate decreased from 1996-2006, with a sharp drop in AIDS-defining illnesses, while non-HIV related diseases like heart disease and liver disease increased, according to CDC analysis.
Researchers at Gladstone Institute of Virology and Immunology discover how HIV promotes the death of CD4 T cells by infecting them with a failed form of viral replication. This process leads to the depletion of these critical immune cells, ultimately causing AIDS.
Researchers at IRCM identified a mechanism regulating activation-induced deaminase, which could lead to new therapies for some types of lymphoma and leukemia. The discovery found that Hsp90 inhibition destabilizes AID, preventing uncontrolled gene mutation and accelerating disease progression.
Northwestern University is part of a US-led initiative to modernize medical school curricula in Nigeria, enhancing knowledge and skills among medical students. The project aims to retain 140,000 new healthcare workers and improve primary health care capacity across Africa.
Dr. Douglas A. Jabs has been recognized by the American Academy of Ophthalmology with the Jackson Memorial Lecture for his decades-long study on cytomegalovirus retinitis and its interaction with HIV. His research aims to improve clinical outcomes in patients with AIDS and CMV retinitis.
Scientists at IRB Barcelona discover that raltegravir cancels function of essential protein in herpesvirus replication, offering potential target for new drug development. Human cytomegalovirus, the most deadly and widespread herpes virus, shows vulnerability to raltegravir treatment.
Minister Tedros Adhanom Ghebreyesus advocates for 'country ownership' to maximize development aid impact. Countries must have clear vision and control over resources, allowing them to tailor proven practices to their specific circumstances.
A recent study by IRCM researchers revealed the crucial role of the Vpr protein in blocking cell division and triggering immune cell death during HIV infection. The findings suggest that targeting this process could lead to new potential therapeutic targets, providing a better understanding of HIV infection and AIDS.
A new method of attack against the AIDS virus has been developed using a prevention system that stiffens cell membranes, making them impenetrable to the virus. This research, published in Chemistry & Biology, provides a novel focus on regulating cell membrane fluidity and preventing viral fusion.
The XVIII International AIDS Conference presented strong scientific findings on HIV research and program scale-up, emphasizing the need for increased funding and human rights protection. Delegates renewed their commitment to securing universal access to prevention, care, treatment, and support.
Georgian leaders sign Vienna Declaration to strengthen call for science-based drug policy, emphasizing harm reduction and evidence-based treatment. The declaration aims to improve community health and safety by incorporating scientific evidence into illicit drug policies.
The International AIDS Society launches a new report recommending a science-based approach to scaling up treatment and prevention of HIV amongst Injecting Drug Users (IDUs). The 'Seek, test, treat and retain' model advocates for expanding outreach, testing, treatment, and retention services within the criminal justice system.
The lack of access to scientifically proven interventions for key populations at risk and the lagging scale-up of treatment regimens threaten future progress on AIDS. Organizers call for an end to passive neglect and active denial of life-saving health services, information, and tools.
The International AIDS Conference promotes novel treatment methods, antiretroviral-based prevention options and the development of a cure. Key findings include the potential use of antiretroviral drugs to prevent infections and the need for universal access to lifesaving treatment.
Researchers gathered for a workshop to review and debate the latest research on HIV reservoirs, with the goal of controlling or eradicating the virus. Despite advances in antiretroviral therapy, HIV remains hidden in certain cells, making lifelong treatment necessary.
The CAPRISA 004 trial results demonstrate the effectiveness of a 1% tenofovir gel in reducing a woman's risk of HIV transmission. This breakthrough provides a tool for women to take control of their health and protect themselves from HIV infection.
The new guidelines recommend initiating antiretroviral treatment (ART) as soon as possible for asymptomatic individuals with low CD4+ cell counts, and treating symptomatic patients regardless of their CD4+ count. The treatment should be individualized based on concurrent conditions and previous drug exposure.
The International AIDS Society (IAS) has announced the winners of four prestigious scientific awards, recognizing innovative HIV and AIDS research. The Women, Girls and HIV Investigator Prize was awarded to Naina Rani for her work on mainstreaming the Prevention of Parent to Child Transmission program in India.
The International AIDS Society has awarded $3.4 million in grants to 10 early-stage researchers from diverse scientific disciplines, aiming to advance HIV understanding and prevention approaches. The grantees will collaborate with CFAR institutions to explore pressing scientific questions on long-term survival and HIV transmission.
Three former Latin American presidents have signed the Vienna Declaration, calling for the incorporation of scientific evidence into illicit drug policies. The declaration aims to improve community health and safety by reducing consumption and harm caused by drugs.
The Fogarty International Center of the NIH has awarded a five-year, $3.6 million grant to an international AIDS training and research program to continue training foreign researchers in developing countries. The program supports established research training programs in India, Cambodia, the Philippines, and Kenya, and will also focus ...
Experts warn that failure to meet universal access pledge and budget cuts to prevention and treatment programs will deliver a major setback. Many African countries face depleting stocks of antiretroviral medications and reduced treatment coverage goals, increasing the risk of HIV drug resistance.
The Vienna Declaration urges governments and international organizations to adopt evidence-based approaches to illicit drug policy, recognizing addiction as a medical condition. This declaration aims to reduce harms deriving from current policies and redirect resources towards prevention, treatment, and harm reduction interventions.
The International AIDS Society calls on donors to uphold their commitment to universal access to HIV prevention, treatment, and care by 2015. Failure to do so would lead to a surge in infections, illness, and death, undermining the credibility of the G8.
The Canadian Medical Association Journal suggests relaxing the ban on male blood donors who have had sex with men, citing a significant decrease in false negative test results. The proposed change could lead to an expansion of the blood donor pool, resulting in more units of blood available for transfusions.
Almost 50% of AIDS patients died from AIDS, but non-AIDS related deaths increased after four years of treatment with ART. Lifestyle-related causes like suicide and liver disease were common non-AIDS deaths.
The International Treatment Preparedness Group's new report documents early warning signs of devastating impact from global pullback on AIDS commitment and funding. People living with HIV often struggle to afford medicines for opportunistic infections, transport costs, food, and second-line medications.
Researchers tracked monocytes in primates infected with simian immunodeficiency virus to find that increased turnover predicts rapid AIDS development and brain disease severity. The study identifies a marker, soluble CD163, exclusive to monocytes, which correlates with disease progression.
In Ghana, large-scale intervention programs have convinced people to trust medical explanations for diseases like HIV/AIDS, overcoming traditional beliefs in witchcraft. The success of long-term health initiatives in Northern regions has shown that education and community engagement can lead to better health outcomes.